A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Protocol No

ECOG-EA7222

Staff Member

John Charlson

Phase

III

Summary

This study is being done to answer the following question: Can adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) help patients with certain types of cancer live longer without having disease progression?

Objective

Study of immunotherapy + chemo for patients with aggressive poorly differentiated sarcomas

Status

OPEN TO ACCRUAL